OpenEvidence vs UpToDate vs DynaMed: Ranked (2026)

ECRI’s 2026 Health Technology Hazard Report placed “misuse of AI chatbots in healthcare” at #1 on its annual list — above cyberattacks, device recalls, and supply chain failures. That ranking didn’t emerge from speculation. ECRI documented the actual harms: incorrect diagnoses, unnecessary testing recommendations, fabricated anatomical information, and one case where an AI chatbot approved a dangerous electrosurgical return electrode placement technique that no competent clinician would have endorsed.

If you’re deciding whether to keep renewing UpToDate at ~$559/year, switch to OpenEvidence (free for NPI-verified clinicians), move to DynaMed, or try Glass Health — this is not just a financial decision. Every AI clinical decision support tool you use at the point of care is a patient safety decision.

Short answer: OpenEvidence is the best free option for bedside evidence retrieval. UpToDate Expert AI remains the strongest for complex topic depth and specialist education. DynaMed + Dyna AI offers the best value among paid platforms. Glass Health is the right pick if you need diagnostic reasoning and ambient scribing in one workflow.

But before ranking anything, we need to establish the framework no vendor comparison will give you: what actually separates a validated clinical decision support tool from a large language model in a white coat.

AI Clinical Decision Support Tools vs. AI Chatbots: The Patient Safety Distinction

ECRI’s #1 hazard designation specifically names ChatGPT, Claude, Copilot, Gemini, and Grok. Not validated clinical decision support platforms. That distinction is intentional and clinical.

A general AI chatbot sources from open internet training data with no clinical governance, no citation transparency, and no editorial update cycle. A validated CDSS sources from curated peer-reviewed literature, discloses its evidence sources, and operates an update cycle designed to reflect current evidence. These are not interchangeable products with different price tags. They represent different patient safety profiles.

ECRI’s documented AI chatbot harms include incorrect diagnoses, unnecessary testing recommendations, AI-generated references to anatomical structures that don’t exist, and documented approval of clinical procedures that would cause direct patient harm. Marcus Schabacker, MD, PhD, ECRI President and CEO, stated: “Medicine is a fundamentally human endeavor. While chatbots are powerful tools, the algorithms cannot replace the expertise, education, and experience of medical professionals.” (ECRI 2026 Health Technology Hazards announcement)

For context on scale: 40 million people per day use ChatGPT for health information, according to ECRI’s analysis of OpenAI data. Most of those users are patients, not clinicians — but the conflation bleeds into clinical settings when general AI tools get embedded in hospital workflows without proper evaluation.

Here’s the honest version of the distinction: not every “AI clinical tool” belongs in the same product category. Consumer-facing AI-powered symptom checkers, general LLMs, and validated CDSS platforms are three different things. Treating them as interchangeable is precisely the category error ECRI is warning against.

Before adopting any AI clinical tool, ask four questions:

1. What is your evidence sourcing, and how is it updated?
2. Has your accuracy been independently validated in a published study?
3. What is your FDA regulatory status?
4. Who can access this tool, and how is that access controlled?

If a vendor can’t answer all four, that’s your answer.

The 4 AI Clinical Decision Support Tools Worth Evaluating

Note: ChatGPT, Gemini, Grok, Claude, and Copilot are not included in this table. Per ECRI’s 2026 hazard report, these tools are not validated for clinical decision-making and are not CDSS products.

Pricing verified March 2026 from dynamedex.com and glass.health/features. UpToDate pricing requires account creation at store.uptodate.com.

Tools that won’t disclose their evidence sourcing should be treated the way you’d treat a pharmaceutical rep who declines to name their data source: with appropriate professional skepticism.

OpenEvidence: The Free Disruptor With a Verification Gate

OpenEvidence entered 2026 as the most disruptive force in clinical decision support, and the trajectory makes that hard to dispute.

As of early 2026: over 40% of US physicians — approximately 430,000 clinicians — are registered users. Monthly clinical consultations exceed 8.5 million. New clinician registrations are running at 65,000 per month. The platform is active in more than 10,000 hospitals. (OpenEvidence Series B announcement, PR Newswire, July 2025; Google Ventures)

That’s not a pilot program. That’s infrastructure.

The verification gate is meaningful. Access requires an NPI number plus secondary documentation — medical school records or a state medical license. This isn’t a checkbox exercise. It limits the platform to credentialed US clinicians, creating both accountability and a product that is genuinely different from a public chatbot. The limitation is that this process is US-centric; international clinicians have limited pathways.

The funding picture is notable but should be read carefully. OpenEvidence raised a $210M Series B at a $3.5B valuation in July 2025 (Google Ventures + Kleiner Perkins), followed by a $250M Series D in January 2026 — total funding exceeding $700M. (BusinessWire, January 2026) The revenue model is advertising, similar to Doximity. A platform that monetizes through advertising has different incentive structures than one that monetizes through subscriptions — worth knowing before you embed it in your practice.

Robert Wachter, MD, Chair of Medicine at UCSF, describes the displacement pattern as analogous to how UpToDate itself displaced medical textbooks 25 years ago. The shift is documented and accelerating.

The community picture is more mixed. From a Sermo physician poll: “Evidence-based Medicine is a tenet of our clinical acumen and OpenEvidence AI can make this accessible on the wards and at the bedside” — a pediatric specialist. Dr. Sanjana Vig, an anesthesiologist, told Healthcare Brew in November 2025: “Getting the information in aggregate on OpenEvidence has been super helpful.”

But also from Sermo: “I don’t trust it because when it’s wrong, it’s annoyingly confident in its wrong answer” — an Internal Medicine physician. A retired physician on financialwisdomforum.org reported hallucinations across more than 1,220 searches, particularly on complex and rare disease queries.

Our take: OpenEvidence is legitimately different from a chatbot. The verification gate is meaningful, the citation model is transparent, and the scale of adoption among credentialed clinicians reflects actual clinical utility. But “annoyingly confident when wrong” is a clinical risk that deserves to be named, not buried. For routine evidence retrieval and bedside quick reference, OpenEvidence is a strong tool. For complex rare disease presentations, use it as a starting point, not an endpoint. It is a reference tool that augments your judgment. It is not a consult.

UpToDate Expert AI: The Gold Standard Playing Catch-Up

UpToDate’s Expert AI launched in October 2025. DynaMed’s Dyna AI launched in July 2024. That’s 15 months of distance — and in a market moving as fast as AI-assisted CDSS, that gap is significant.

Jonathan Chen, MD, a Stanford hospitalist, told STAT News in October 2025: “It’s the obvious thing to do… And their lunch is being eaten right now.” That’s not a hostile take. It’s an accurate one.

Pricing: UpToDate’s individual subscription (Pro Plus, which includes Expert AI) runs approximately $499–600/year. The exact figure requires going through store.uptodate.com — Wolters Kluwer doesn’t display it publicly. That practice is frustrating in a market where competitors post pricing on a public page.

Where UpToDate still leads: depth, narrative quality, and editorial coverage. The platform covers 25 specialties with expert-authored summaries refined over decades. In a 2021 University of Toronto crossover study, 88% of participants reported enjoying the UpToDate format versus 62% for DynaMed — a preference gap that reflects the quality of the writing, not just the information. (iatrox.com DynaMed vs. UpToDate comparison) Institutional memory and editorial oversight cannot be replicated quickly with an AI layer.

The usage pattern as of 2026: Most clinicians now use OpenEvidence for rapid bedside look-up; UpToDate has shifted toward “the final word” for complex topic reviews and educational deep-dives. One retired physician on financialwisdomforum.org described it clearly: “For teaching purposes I have reverted to (non AI) UpToDate. For a quick clinical question in an area I am not familiar with, I use OpenEvidence.”

That bifurcation has pricing implications. The case for paying $499–600/year rests on complex specialist cases and educational use — not on general query speed or AI feature parity with a free tool.

Our take: UpToDate’s editorial depth is real and the institutional authority is not marketing. Expert AI is a necessary catch-up move — it adds AI capability to a platform that needed it — but it doesn’t change the value calculus for primary care clinicians who can get equivalent bedside speed from OpenEvidence for free. If you’re a specialist managing complex cases or an attending using it for teaching, the premium is justified. If you’re in primary care handling routine queries, that math is harder to make work.

DynaMed + Dyna AI: The Evidence-Graded Alternative

DynaMed launched Dyna AI in July 2024, over a year before UpToDate Expert AI reached clinicians. That’s not a trivial lead. Dyna AI has had more than 15 months of live deployment, iteration, and real-world clinical feedback before its main competitor’s AI feature went live.

Pricing is straightforward (unlike some competitors): $399/year without Dyna AI, $475/year with Dyna AI, $149/year for students. Comes with a 30-day free trial and 60-day money-back guarantee. (dynamedex.com/individual-subscriptions/) The $76/year difference versus UpToDate with Dyna AI adds up — and it’s a gap with evidence behind it.

The validation picture: A 2021 University of Toronto crossover study published in Applied Clinical Informatics found DynaMed Plus and UpToDate statistically noninferior on accuracy — DynaMed scored 1.36/2 versus UpToDate’s 1.35/2. Two tools operating at equivalent accuracy tiers, not two tools with a meaningful performance gap.

What differentiates DynaMed: its three-tier evidence grading system. Recommendations are tagged Level 1 (strong evidence, benefit outweighs harm), Level 2 (moderate evidence), or Level 3 (limited evidence or expert opinion). You’re not just seeing the recommendation — you’re seeing the quality of evidence behind it. This is evidence-based medicine made explicit in the interface. UpToDate does not match this transparency.

DynaMed covers 35+ specialties versus UpToDate’s 25, updates multiple times daily, and — in January 2026 — DynaMedex won the #1 Best in KLAS award for Point-of-Care Disease Reference. (Merative blog) First time DynaMed has held that ranking.

DynaMed also joined the Coalition for Health AI (CHAI) in September 2024 — a third-party AI governance framework that UpToDate has not joined. The governance posture matters when you’re evaluating AI tools for clinical use.

A practical note for American College of Physicians members: ACP membership includes DynaMedex access as a membership benefit, which eliminates the subscription cost entirely for qualifying members.

Our take: DynaMed’s evidence grading system is the most transparent of the paid platforms. If you want to understand why a recommendation is being made — not just what it is — DynaMed shows you the evidence quality explicitly. At $76/year less than UpToDate with Dyna AI, with the Best in KLAS 2026 ranking and CHAI governance membership, it’s worth a 30-day trial before you auto-renew UpToDate.

Glass Health: The Right Pick if You Need CDSS and Scribing in One

Glass Health is solving a different problem than UpToDate or DynaMed, and it’s worth being precise about that.

The product is a hybrid: ambient scribing, three-tier differential diagnosis generation, Assessment and Plan generation, and clinical Q&A against physician-maintained evidence-based guidelines. It is not a reference library. For established clinical topics where you need authoritative narrative depth, Glass Health is not the right tool.

Pricing tiers:

• Lite (free): Access for medical students and trainees — no subscription barrier
• Starter ($20/month): Core clinical workflow features
• Pro ($90/month): Full feature set including differential reasoning and ambient scribing
• Max ($200/month): Adds EHR integration via SMART on FHIR (Epic, eClinicalWorks, Athena)

(glass.health/features)

That jump from $90 to $200/month for EHR integration is significant. If your workflow depends on native EHR documentation, you’re looking at $2,400/year for Max — a real commitment relative to the paid CDSS alternatives.

Where Glass Health genuinely adds value: For residents and trainees developing diagnostic reasoning, the structured three-tier differential output functions as a teaching tool as much as a clinical one. For clinicians already paying for a separate ambient scribe tool, consolidating into a single platform has legitimate workflow logic. For complex case brainstorming where a structured differential is the deliverable, Glass Health’s design is purpose-built.

The honest limitation: Glass Health has no published independent accuracy studies as of 2026. The clinical guidelines are physician-maintained, which is the right architecture, but there’s a meaningful gap between “physician-maintained guidelines” and “independently validated accuracy.” It is not a reference library replacement.

Our take: Glass Health is solving the diagnostic reasoning and documentation integration problem, and that problem is real. The free and Starter tiers offer genuine value for trainees with no financial barrier. For attending physicians who need a curated evidence database for reference queries, it doesn’t replace UpToDate or DynaMed — it solves a different problem. Match the tool to your actual use case, not to its marketing.

Our Take: Stop Asking “Which Is Best” — Start Asking “Validated for What?”

The AMA’s 2026 Physician Survey, covering 1,692 physicians, found that 81% of physicians now use AI professionally — up from 38% in 2023. (AMA, ama-assn.org/system/files/physician-ai-sentiment-report.pdf) That’s more than a doubling in three years.

The same survey found that 88% of physicians want more rigorous safety and efficacy validation before AI tools become widespread. These are not technophobes resisting change. These are clinicians watching AI get deployed at scale without the validation infrastructure that clinical practice requires — and responding to documented evidence, not instinct.

ECRI named AI chatbot misuse the #1 hazard for 2026 because that validation gap is actively causing patient harm. The two data points belong together.

Recommendation by role:

• Primary care, daily bedside reference: OpenEvidence. Free, fast, NPI-verified, transparent citations. No subscription to justify.
• Specialist depth and complex topic education: UpToDate Expert AI. Deepest editorial coverage, narrative quality no AI layer has yet matched, worth the premium for complex-case-heavy workflows.
• Evidence-graded summaries, best paid value: DynaMed + Dyna AI. Noninferior accuracy, 15+ months of live AI deployment, $76/year less than UpToDate with Dyna AI, Best in KLAS 2026, CHAI governance membership.
• Differential reasoning + documentation integration: Glass Health Pro.

What not to use for clinical decisions: ChatGPT, Gemini, Claude, Grok, Copilot. ECRI named these tools specifically. The fact that they can produce medically formatted text is the hazard, not the feature. Confident tone in clinical language is not clinical accuracy.

One orthopedic surgeon on Sermo said it plainly: “The signature at the bottom of the diagnostic report is always MINE and I am responsible for medical-legal purposes.” (Sermo, sermo.com/resources/openevidence-ai/) No AI tool changes that accountability. Validation matters precisely because the liability doesn’t transfer.

The three-question vendor test — ask before adopting any AI clinical tool:

1. What is your evidence sourcing and update cycle?
2. Has your accuracy been independently validated in a published study?
3. What is your FDA regulatory status?

If a vendor can’t answer all three clearly, that is the complete answer.

Frequently Asked Questions

Is OpenEvidence safe to use for clinical decisions?

OpenEvidence sources from peer-reviewed literature with transparent citations and requires NPI verification — this places it in a materially different category from general AI chatbots. For evidence retrieval and quick reference, it is a well-designed tool. It is not a replacement for clinical judgment on complex presentations, and community reports of confident-but-incorrect responses on rare or complex queries are worth taking seriously. Treat it as a reference tool that surfaces evidence, not an authority that replaces reasoning.

What is the difference between an AI chatbot and a clinical decision support tool?

A general AI chatbot — ChatGPT, Gemini, Grok — sources from internet training data with no clinical governance, no citation transparency, and no validation for healthcare use. A validated CDSS sources from curated peer-reviewed literature, discloses its evidence sources, operates an editorial update cycle, and has typically been studied for clinical accuracy. ECRI’s 2026 #1 hazard designation targets the chatbot category specifically, not validated CDSS platforms. That distinction has patient safety implications.

Is UpToDate being replaced by AI tools?

OpenEvidence has registered 40%+ of US physicians as daily users and is displacing UpToDate as the first-stop bedside reference — particularly among trainees. Robert Wachter, MD (UCSF), describes the pattern as analogous to how UpToDate displaced medical textbooks. “Replaced” is too simple, though: UpToDate Expert AI retains clear leadership for complex topic depth and specialist education. The more accurate picture is displacement for speed and routine queries, while UpToDate holds authority for complex cases.

Which AI clinical decision support tools are FDA cleared or clinically validated?

None of the major AI CDSS tools discussed here — OpenEvidence, UpToDate Expert AI, DynaMed, or Glass Health — are FDA cleared as medical devices. On clinical accuracy: DynaMed and UpToDate were found noninferior to each other in a 2021 University of Toronto study published in Applied Clinical Informatics. OpenEvidence claims a perfect USMLE score — a self-reported figure without published independent replication. Independent peer-reviewed accuracy studies for AI-specific features (Dyna AI, Expert AI) are limited as of 2026.

Can I use ChatGPT or Gemini for clinical decisions?

ECRI’s #1 health technology hazard for 2026 is explicitly the misuse of AI chatbots in clinical settings, naming ChatGPT, Claude, Copilot, Gemini, and Grok. These tools are not designed, validated, or regulated for clinical decision-making. Documented harms include incorrect diagnoses, unnecessary testing recommendations, and approval of dangerous procedural techniques. The professional consensus from ECRI and the AMA is clear: use validated CDSS tools for clinical decisions, not general-purpose AI.

How accurate is AI clinical decision support compared to a specialist consultation?

Not consistently equivalent, and the published data is limited. The 2021 crossover study found UpToDate and DynaMed achieving equivalent accuracy at modest scores — approximately 1.35–1.36 out of 2. That’s noninferior to each other; it is not a claim about specialist consultation accuracy. Physician community experience is split: reliable on familiar topics, problematic on complex or rare disease presentations. AI CDSS augments clinical reasoning — it doesn’t substitute for a specialist who has examined the patient.

The Baseline Has Changed — but the Stakes Haven’t

The best AI clinical decision support tool is the one with transparent evidence sourcing, independently validated accuracy, and a meaningful verification gate — not the one with the highest valuation or the most confident marketing pitch.

Before renewing any subscription or adopting a new AI clinical tool, run it through the three-question framework: evidence sourcing and update cycle, independent accuracy validation, regulatory status. Then match the tool to your actual workflow — OpenEvidence for bedside speed, UpToDate Expert AI for specialist depth, DynaMed for evidence-graded value, Glass Health if you need diagnostics and documentation in one place.

If your institution is also evaluating best AI medical scribes for doctors, the same validation framework applies. For telehealth-based practices, the same clinical standards hold — see our guide on how to prepare for a telehealth appointment for the patient-side perspective on AI-assisted clinical encounters. The questions don’t change by product category, and neither do the stakes for getting it wrong.

ECRI put AI chatbot misuse at #1 for a reason — and every clinician who knows the difference between a validated CDSS and a confident LLM makes that list one person shorter.